Anavex Life Sciences Corp. Stock News

The FDA approves GSK's Priorix vaccine for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months and older.

Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.

Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.

Aeglea (AGLE) gets a Refusal to File letter from the FDA related to the biologics license application for pegzilarginase to treat arginase 1 deficiency. Stock down.

Directly or indirectly, peroxynitrite is responsible for much of the damage done to the brain in Alzheimer's disease. As a sigma-1 agonist, blarcamesine limits peroxynitrite formation by inhibiting in

As the recent Rett syndrome controversy shows, Anavex is a perpetually beleaguered stock. Despite the tremendous bearish headwind it always faces, the company has been able to increase shareholder val

The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable

The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeut

AVXL earnings call for the period ending March 31, 2022.

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President &

Company to host a webcast today at 4:30 p.m. Eastern Time

Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape